Wanjun Bai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wanjun Bai has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Haojing Song
Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, People’s Republic of China
8 shared publicationsBo Qiu
Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, People’s Republic of China
7 shared publicationsYiting Hu
Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, People’s Republic of China
7 shared publicationsCaihui Guo
Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, 050051, People’s Republic of China
5 shared publicationsXue Sun
Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, 050051, People's Republic of China
5 shared publicationsNa Zhao
Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, People’s Republic of China
4 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (24) , e49288
Severe hypokalemia induced by ceftazidime-avibactam: Case report
Rationale: Ceftazidime-avibactam is widely used to treat infections caused by carbapenem-resistant Gram-negative bacteria. Although it is generally considered safe, cases of severe hypokalemia associated with its use have rarely been reported. Patient concerns: A 74-year-old man with severe pneumonia and acute cerebral infarction was treated with ceftazidime-avibactam after sputum culture and nucleic acid testing identified multidrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae . Soon after initiation of therapy, he developed persistent and refractory hypokalemia. Diagnoses: Drug-induced severe hypokalemia secondary to ceftazidime-avibactam was diagnosed. Interventions: Antimicrobial therapy was continued, and the patient received oral spironolactone and nasogastric potassium chloride. Because of persistent hypokalemia and the development of acute kidney injury, the dose of ceftazidime-avibactam was reduced by half. After dose adjustment and continued potassium supplementation, serum potassium levels gradually stabilized. Outcome: The patient’s condition worsened due to multiple organ failure and septic shock. At the request of his family, he was discharged against medical advice. Lessons: This case suggests that avibactam may promote potassium loss by enhancing renal tubular secretion and increasing luminal electronegativity. Clinicians should be aware of this potential adverse effect, particularly in elderly patients or those with renal dysfunction. Close monitoring of serum and urinary potassium levels, along with early correction of abnormalities, is strongly recommended during treatment.
- 12 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (24) , e49288
Open AccessSevere hypokalemia induced by ceftazidime-avibactam: Case report
Rationale: Ceftazidime-avibactam is widely used to treat infections caused by carbapenem-resistant Gram-negative bacteria. Although it is generally considered safe, cases of severe hypokalemia associated with its use have rarely been reported. Patient concerns: A 74-year-old man with severe pneumonia and acute cerebral infarction was treated with ceftazidime-avibactam after sputum culture and nucleic acid testing identified multidrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae . Soon after initiation of therapy, he developed persistent and refractory hypokalemia. Diagnoses: Drug-induced severe hypokalemia secondary to ceftazidime-avibactam was diagnosed. Interventions: Antimicrobial therapy was continued, and the patient received oral spironolactone and nasogastric potassium chloride. Because of persistent hypokalemia and the development of acute kidney injury, the dose of ceftazidime-avibactam was reduced by half. After dose adjustment and continued potassium supplementation, serum potassium levels gradually stabilized. Outcome: The patient’s condition worsened due to multiple organ failure and septic shock. At the request of his family, he was discharged against medical advice. Lessons: This case suggests that avibactam may promote potassium loss by enhancing renal tubular secretion and increasing luminal electronegativity. Clinicians should be aware of this potential adverse effect, particularly in elderly patients or those with renal dysfunction. Close monitoring of serum and urinary potassium levels, along with early correction of abnormalities, is strongly recommended during treatment.
- Open Access
- 5 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Aniracetam restores the excitation-inhibition balance of neurotransmitters in the prefrontal cortex of mice with ADHD
Attention-deficit/hyperactivity disorder (ADHD) is the most prevalent neurodevelopmental disorder in childhood and a common chronic condition among school-aged children. However, the pharmacological mechanisms and pathophysiology of ADHD remain incompletely elucidated. Transmembrane α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor regulatory protein γ-8 (TARP γ-8, also known as calcium voltage-gated channel auxiliary subunit γ8) functions as an auxiliary subunit of AMPA receptors. Previous studies suggest that mice lacking the TARP γ-8 protein may display hyperactivity, impulsivity, and memory deficits, which are hallmarks of ADHD. The nootropic compound aniracetam effectively mitigates ADHD-like symptoms, including hyperactivity, impulsivity, anxiety, cognitive deficits, and memory impairment, observed in adolescent TARP γ-8 knockout (KO) mice. This investigation explored the therapeutic potential of aniracetam and its underlying molecular mechanisms using TARP γ-8 KO mice as an ADHD model. Through cerebral microdialysis coupled with liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis, we identified perturbations in neurotransmitter metabolism in the ADHD model of TARP γ-8 KO mice. Real-time quantitative PCR (RT-qPCR) was employed to detect alterations in the expression of key receptor and transporter genes. The results indicate that aniracetam can alleviate ADHD-related behavioral deficits by modulating the excitatory-inhibitory neurotransmitter systems through the modulation of glutamate receptor, γ-Aminobutyric Acid receptor, and monoamine neurotransmitter transporter expression. These findings in a TARP γ-8-deficient ADHD model support further investigation into aniracetam as a potential therapeutic intervention for ADHD, providing novel molecular targets and a theoretical framework for the pharmacological management of ADHD.
- 5 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessAniracetam restores the excitation-inhibition balance of neurotransmitters in the prefrontal cortex of mice with ADHD
Attention-deficit/hyperactivity disorder (ADHD) is the most prevalent neurodevelopmental disorder in childhood and a common chronic condition among school-aged children. However, the pharmacological mechanisms and pathophysiology of ADHD remain incompletely elucidated. Transmembrane α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor regulatory protein γ-8 (TARP γ-8, also known as calcium voltage-gated channel auxiliary subunit γ8) functions as an auxiliary subunit of AMPA receptors. Previous studies suggest that mice lacking the TARP γ-8 protein may display hyperactivity, impulsivity, and memory deficits, which are hallmarks of ADHD. The nootropic compound aniracetam effectively mitigates ADHD-like symptoms, including hyperactivity, impulsivity, anxiety, cognitive deficits, and memory impairment, observed in adolescent TARP γ-8 knockout (KO) mice. This investigation explored the therapeutic potential of aniracetam and its underlying molecular mechanisms using TARP γ-8 KO mice as an ADHD model. Through cerebral microdialysis coupled with liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis, we identified perturbations in neurotransmitter metabolism in the ADHD model of TARP γ-8 KO mice. Real-time quantitative PCR (RT-qPCR) was employed to detect alterations in the expression of key receptor and transporter genes. The results indicate that aniracetam can alleviate ADHD-related behavioral deficits by modulating the excitatory-inhibitory neurotransmitter systems through the modulation of glutamate receptor, γ-Aminobutyric Acid receptor, and monoamine neurotransmitter transporter expression. These findings in a TARP γ-8-deficient ADHD model support further investigation into aniracetam as a potential therapeutic intervention for ADHD, providing novel molecular targets and a theoretical framework for the pharmacological management of ADHD.
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 7111-7121
Bioequivalence Study of Palbociclib Tablets in Healthy Volunteers
Objective: Bioequivalence of palbociclib tablets was evaluated in healthy volunteers under fasting and fed conditions in this study. Methods: This bioequivalence trial, which randomized subjects to receive palbociclib under fed or fasted conditions, generated these results. High-performance liquid chromatography-mass spectrometry (HPLC-MS) was employed to determine palbociclib concentrations in plasma from collected blood samples. Pharmacokinetic (PK) parameters were calculated using the non-compartmental analysis (NCA) module within Phoenix WinNonlin version 8.2. Statistical analysis of key pharmacokinetic parameters-maximum plasma concentration (Cmax), area under the concentration-time curve from zero to last quantifiable time (AUC0-t), and area under the curve from zero to infinity (AUC0–∞)-was conducted using the bioequivalence (BE) module within WinNonLin. A total of 68 healthy subjects were enrolled and randomized to either a fasted or a fed group. All subjects were randomized into T-R and R-T sequences (T: test formulation; R: reference formulation). Results: The geometric mean ratios (T/R) of Cmax, AUC0-t and AUC0–∞ of palbociclib in plasma were 97.96%, 96.16%, and 96.02% under fasting conditions; The geometric mean ratios (T/R) of Cmax, AUC0-t and AUC0-∞ of palbociclib in plasma were 95.47%, 96.49%, and 96.36% under fed conditions. All 90% confidence intervals for the geometric mean ratios were contained entirely within the range of 80.00% to 125.00%. Under the fasted and fed conditions, the test preparation and the reference preparation of palbociclib tablets were bioequivalent. Adverse events (AEs) occurred at similar rates in the fasted and fed groups. Conclusion: The result indicated that the test preparation and the reference preparation of palbociclib tablets were bioequivalent under the fasted and fed conditions. The safety of the two preparations was good. Clinical Trial Registration: This trial was registered on the Chinese Clinical Trial website (http://www.chinadrugtrials.org.cn/index.html # CTR20220977).
- 1 August 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 7111-7121
Open AccessBioequivalence Study of Palbociclib Tablets in Healthy Volunteers
Objective: Bioequivalence of palbociclib tablets was evaluated in healthy volunteers under fasting and fed conditions in this study. Methods: This bioequivalence trial, which randomized subjects to receive palbociclib under fed or fasted conditions, generated these results. High-performance liquid chromatography-mass spectrometry (HPLC-MS) was employed to determine palbociclib concentrations in plasma from collected blood samples. Pharmacokinetic (PK) parameters were calculated using the non-compartmental analysis (NCA) module within Phoenix WinNonlin version 8.2. Statistical analysis of key pharmacokinetic parameters-maximum plasma concentration (Cmax), area under the concentration-time curve from zero to last quantifiable time (AUC0-t), and area under the curve from zero to infinity (AUC0–∞)-was conducted using the bioequivalence (BE) module within WinNonLin. A total of 68 healthy subjects were enrolled and randomized to either a fasted or a fed group. All subjects were randomized into T-R and R-T sequences (T: test formulation; R: reference formulation). Results: The geometric mean ratios (T/R) of Cmax, AUC0-t and AUC0–∞ of palbociclib in plasma were 97.96%, 96.16%, and 96.02% under fasting conditions; The geometric mean ratios (T/R) of Cmax, AUC0-t and AUC0-∞ of palbociclib in plasma were 95.47%, 96.49%, and 96.36% under fed conditions. All 90% confidence intervals for the geometric mean ratios were contained entirely within the range of 80.00% to 125.00%. Under the fasted and fed conditions, the test preparation and the reference preparation of palbociclib tablets were bioequivalent. Adverse events (AEs) occurred at similar rates in the fasted and fed groups. Conclusion: The result indicated that the test preparation and the reference preparation of palbociclib tablets were bioequivalent under the fasted and fed conditions. The safety of the two preparations was good. Clinical Trial Registration: This trial was registered on the Chinese Clinical Trial website (http://www.chinadrugtrials.org.cn/index.html # CTR20220977).
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 6061-6072
High-Fat Meal Increase Blonanserin Bioavailability 5-Fold in Chinese Healthy Subjects
Purpose: Although blonanserin is widely used in clinical practice, existing studies have shown significant variations in the magnitude of food effects on its pharmacokinetics. This study was conducted to evaluate the impact of food on the pharmacokinetics and safety of 4-mg blonanserin tablets in healthy Chinese subjects. Methods: The findings were derived from a bioequivalence study in which subjects were randomly assigned to receive blonanserin tablets under fasting or fed conditions. Serial blood samples were collected and plasma concentrations of blonanserin were accurately determined using a validated high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). Pharmacokinetic parameters, including the maximum plasma concentration (Cmax), the area under the concentration-time curve from zero to the last quantifiable time point (AUC0-t), and the area under the concentration-time curve from zero to infinity (AUC0–∞) were estimated using the non-compartmental method and statistically analyzed by the BE module of WinNonLin. Safety assessments were performed throughout the study period. Results: 106 healthy subjects were enrolled and divided into a fasted group and a fed group. The Cmax, AUC0-t and AUC0–∞ of blonanserin in plasma after a high-fat meal increased 5.23-fold, 4.77-fold and 4.82-fold, relative to the fasted conditions. The 90% confidence interval (90% CI) were outside the 80.00– 125.00% range. The incidence of adverse drug reaction (ADR) was similar between the fasted group and the fed group, with the majority being mild in severity. Conclusion: The results revealed that a high-fat meal significantly increased blonanserin bioavailability by approximately 5-fold at the 4-mg dose. Blonanserin was well tolerated in most subjects under both fasting and fed conditions, and food intake did not significantly alter its safety profile. These findings highlight the need to consider food effects when determining clinical dosing regimens.
- 1 July 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 6061-6072
Open AccessHigh-Fat Meal Increase Blonanserin Bioavailability 5-Fold in Chinese Healthy Subjects
Purpose: Although blonanserin is widely used in clinical practice, existing studies have shown significant variations in the magnitude of food effects on its pharmacokinetics. This study was conducted to evaluate the impact of food on the pharmacokinetics and safety of 4-mg blonanserin tablets in healthy Chinese subjects. Methods: The findings were derived from a bioequivalence study in which subjects were randomly assigned to receive blonanserin tablets under fasting or fed conditions. Serial blood samples were collected and plasma concentrations of blonanserin were accurately determined using a validated high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). Pharmacokinetic parameters, including the maximum plasma concentration (Cmax), the area under the concentration-time curve from zero to the last quantifiable time point (AUC0-t), and the area under the concentration-time curve from zero to infinity (AUC0–∞) were estimated using the non-compartmental method and statistically analyzed by the BE module of WinNonLin. Safety assessments were performed throughout the study period. Results: 106 healthy subjects were enrolled and divided into a fasted group and a fed group. The Cmax, AUC0-t and AUC0–∞ of blonanserin in plasma after a high-fat meal increased 5.23-fold, 4.77-fold and 4.82-fold, relative to the fasted conditions. The 90% confidence interval (90% CI) were outside the 80.00– 125.00% range. The incidence of adverse drug reaction (ADR) was similar between the fasted group and the fed group, with the majority being mild in severity. Conclusion: The results revealed that a high-fat meal significantly increased blonanserin bioavailability by approximately 5-fold at the 4-mg dose. Blonanserin was well tolerated in most subjects under both fasting and fed conditions, and food intake did not significantly alter its safety profile. These findings highlight the need to consider food effects when determining clinical dosing regimens.
- Open Access
- 21 March 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1512857
The effect of high-fat diet on the pharmacokinetics of ondansetron hydrochloride tablets in healthy Chinese subjects
Background: This study aimed to assess how a high-fat diet impacts the pharmacokinetics and safety characteristics of 8 mg Ondansetron hydrochloride tablets among healthy Chinese individuals.Subjects and methods: The findings presented here were obtained from a bioequivalence study, in which individuals were randomly assigned to consume Ondansetron hydrochloride tablets either following a meal or subsequent to a high-fat diet containing 978.6 kcal, with 54.6% of the calories derived from fat. The plasma concentrations of Ondansetron were measured through the utilization of high-performance liquid chromatography-mass spectrometry (LC-MS/MS) after collecting blood samples. For the computation of pharmacokinetic parameters, the non-compartmental module from Phoenix WinNonlin Version 8.2 was utilized Additionally, the BE module within WinNonLin was utilized to statistically analyze key pharmacokinetic metrics, including the maximum level of concentration (Cmax), the area beneath the concentration-time curve spanning from zero to the final quantifiable time point (AUC0-t), and the area beneath the concentration-time curve extending from zero to a theoretical limitless point (AUC0–∞) in plasma. A total of 53 healthy subjects participated in the study and were divided into a fasted cohort and a postprandial cohort.Results: Ondansetron had lower Cmax, AUC0–t, and AUC0–∞in plasma when taken with food compared to when taken on an empty stomach, with the 90% confidence interval falling outside the acceptable range of 80.00%–125.00%.The occurrence of treatment-related side effects was comparable in both the fasted and postprandial groups, as was the incidence of adverse drug reactions.Conclusion: The study concluded that the high-fat meal had a notable impact on how Ondansetron is processed in the body. Healthy subjects tolerated all treatments well and safely under both postprandial and fasted conditions.Clinical Trial Registration: http://www.chinadrugtrials.org.cn/index.html, identifier CTR20213116.
- 21 March 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1512857
Open AccessThe effect of high-fat diet on the pharmacokinetics of ondansetron hydrochloride tablets in healthy Chinese subjects
Background: This study aimed to assess how a high-fat diet impacts the pharmacokinetics and safety characteristics of 8 mg Ondansetron hydrochloride tablets among healthy Chinese individuals.Subjects and methods: The findings presented here were obtained from a bioequivalence study, in which individuals were randomly assigned to consume Ondansetron hydrochloride tablets either following a meal or subsequent to a high-fat diet containing 978.6 kcal, with 54.6% of the calories derived from fat. The plasma concentrations of Ondansetron were measured through the utilization of high-performance liquid chromatography-mass spectrometry (LC-MS/MS) after collecting blood samples. For the computation of pharmacokinetic parameters, the non-compartmental module from Phoenix WinNonlin Version 8.2 was utilized Additionally, the BE module within WinNonLin was utilized to statistically analyze key pharmacokinetic metrics, including the maximum level of concentration (Cmax), the area beneath the concentration-time curve spanning from zero to the final quantifiable time point (AUC0-t), and the area beneath the concentration-time curve extending from zero to a theoretical limitless point (AUC0–∞) in plasma. A total of 53 healthy subjects participated in the study and were divided into a fasted cohort and a postprandial cohort.Results: Ondansetron had lower Cmax, AUC0–t, and AUC0–∞in plasma when taken with food compared to when taken on an empty stomach, with the 90% confidence interval falling outside the acceptable range of 80.00%–125.00%.The occurrence of treatment-related side effects was comparable in both the fasted and postprandial groups, as was the incidence of adverse drug reactions.Conclusion: The study concluded that the high-fat meal had a notable impact on how Ondansetron is processed in the body. Healthy subjects tolerated all treatments well and safely under both postprandial and fasted conditions.Clinical Trial Registration: http://www.chinadrugtrials.org.cn/index.html, identifier CTR20213116.
- Open Access
- 21 March 2025
- Published by Society for Neuroscience in eneuro
- Vol. 12 (3)
Aniracetam Ameliorates Attention Deficit Hyperactivity Disorder Behavior in Adolescent Mice
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects 8–12% of children globally. Hyperactivity-related behaviors, as well as inattention and impulsivity, are regarded as the nuclear symptoms of ADHD. At present, its etiologies and risk factors are unknown. Previous research linked TARP γ-8 deficiency to ADHD-like behaviors in mice, including hyperactivity, impulsivity, and memory deficits. Aniracetam, a nootropic drug, enhances cognition by modulating cholinergic activity and glutamate receptors, offering neuroprotective effects. This study examined TARP γ-8 knockout (KO) mice at 4 and 8 weeks, assessing behaviors through locomotor activity, cliff avoidance, novel object recognition, and contextual fear conditioning tests. TARP γ-8 KO mice exhibited hyperactivity, reduced recognition memory, and impaired short-term memory and long-term memory. Aniracetam administration improved these behavioral deficits, suggesting its potential as a therapeutic agent for ADHD. The findings align with ADHD’s pathophysiology, resembling the neurological impairments in TARP γ-8 KO mice. Aniracetam shows promise as a novel treatment for ADHD symptoms, highlighting its therapeutic value.
- 21 March 2025
- Published by Society for Neuroscience in eneuro
- Vol. 12 (3)
Open AccessAniracetam Ameliorates Attention Deficit Hyperactivity Disorder Behavior in Adolescent Mice
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects 8–12% of children globally. Hyperactivity-related behaviors, as well as inattention and impulsivity, are regarded as the nuclear symptoms of ADHD. At present, its etiologies and risk factors are unknown. Previous research linked TARP γ-8 deficiency to ADHD-like behaviors in mice, including hyperactivity, impulsivity, and memory deficits. Aniracetam, a nootropic drug, enhances cognition by modulating cholinergic activity and glutamate receptors, offering neuroprotective effects. This study examined TARP γ-8 knockout (KO) mice at 4 and 8 weeks, assessing behaviors through locomotor activity, cliff avoidance, novel object recognition, and contextual fear conditioning tests. TARP γ-8 KO mice exhibited hyperactivity, reduced recognition memory, and impaired short-term memory and long-term memory. Aniracetam administration improved these behavioral deficits, suggesting its potential as a therapeutic agent for ADHD. The findings align with ADHD’s pathophysiology, resembling the neurological impairments in TARP γ-8 KO mice. Aniracetam shows promise as a novel treatment for ADHD symptoms, highlighting its therapeutic value.
- Open Access
- 1 March 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 1853-1868
Bioequivalence Study of Single-Pill Capsule Formulation of Amlodipine Plus Benazepril in Healthy Chinese Subjects Under Fasting and Fed Conditions
Background: The aim of the study was to evaluate the pharmacokinetic (PK) properties and safety profiles of test and reference amlodipine/benazepril capsules under both fasting and fed states, determine the bioequivalence between the two formulations, and provide sufficient evidence for new drug application. Subjects and Methods: The bioequivalence study was conducted utilizing a randomized, open-label design, involving two formulations administered in a single-dose format. Healthy Chinese participants who met the eligibility criteria were administered a single dose of the test or reference amlodipine/benazepril capsule. Blood samples were taken serially for up to 168 hours post-administration during each period, and the plasma levels of amlodipine, benazepril, and benazeprilat were measured using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method. For bioequivalence evaluation, geometric mean ratios comparing the pharmacokinetic parameters of the test drug with those of the reference drug were calculated along with their corresponding 90% confidence intervals. Safety assessments were conducted throughout the duration of the study. Results: The PK parameters of the test formulation were found to be comparable to those of the reference formulation under both fasting and fed conditions. The 90% confidence intervals (CIs) for the geometric mean ratios comparing the test and reference formulations for the peak concentration (Cmax), the area under the curve from time zero to the last measurable concentration (AUC0-t), and the area under the curve from time zero to observed infinity (AUC0-∞) of amlodipine, benazepril, and benazeprilat fell within the range of 80.00% to 125.00% in both groups. Both formulations were well tolerated by participants, with no serious adverse events reported throughout the trial. Conclusion: The pharmacokinetic bioequivalence between the test and reference formulation in healthy individuals was confirmed under both fasting and fed states, meeting regulatory standards set for the study. Both drug formulations demonstrated safety and tolerability.
- 1 March 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 1853-1868
Open AccessBioequivalence Study of Single-Pill Capsule Formulation of Amlodipine Plus Benazepril in Healthy Chinese Subjects Under Fasting and Fed Conditions
Background: The aim of the study was to evaluate the pharmacokinetic (PK) properties and safety profiles of test and reference amlodipine/benazepril capsules under both fasting and fed states, determine the bioequivalence between the two formulations, and provide sufficient evidence for new drug application. Subjects and Methods: The bioequivalence study was conducted utilizing a randomized, open-label design, involving two formulations administered in a single-dose format. Healthy Chinese participants who met the eligibility criteria were administered a single dose of the test or reference amlodipine/benazepril capsule. Blood samples were taken serially for up to 168 hours post-administration during each period, and the plasma levels of amlodipine, benazepril, and benazeprilat were measured using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method. For bioequivalence evaluation, geometric mean ratios comparing the pharmacokinetic parameters of the test drug with those of the reference drug were calculated along with their corresponding 90% confidence intervals. Safety assessments were conducted throughout the duration of the study. Results: The PK parameters of the test formulation were found to be comparable to those of the reference formulation under both fasting and fed conditions. The 90% confidence intervals (CIs) for the geometric mean ratios comparing the test and reference formulations for the peak concentration (Cmax), the area under the curve from time zero to the last measurable concentration (AUC0-t), and the area under the curve from time zero to observed infinity (AUC0-∞) of amlodipine, benazepril, and benazeprilat fell within the range of 80.00% to 125.00% in both groups. Both formulations were well tolerated by participants, with no serious adverse events reported throughout the trial. Conclusion: The pharmacokinetic bioequivalence between the test and reference formulation in healthy individuals was confirmed under both fasting and fed states, meeting regulatory standards set for the study. Both drug formulations demonstrated safety and tolerability.
- Open Access
- 29 October 2024
- Published by Springer Nature in Drugs in R&D
- Vol. 24 (4) , 531-538
Bioequivalence Analysis of Ondansetron Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Two-Period Crossover Phase I Study
Background Ondansetron is a highly selective 5-HT3 receptor antagonist that alleviates nausea and vomiting. Bioequivalence evaluation ensures that the efficacy of generic drugs is consistent with that of the original drug. Objective The objective of this study was to evaluate the bioequivalence of ondansetron hydrochloride (HCl) tablets taken in single doses under fasting and postprandial conditions in healthy subjects. Methods In this randomized, open-label, two-cycle, crossover phase I study, liquid chromatography‒tandem mass spectrometry (LC‒MS/MS) was used to determine the ondansetron concentration in dipotassium-ethylenediaminetetraacetate (K2-EDTA) plasma after the subjects received a single 8 mg of ondansetron and reference formulation. Twenty-six healthy subjects received one tablet of ondansetron under fasting conditions and 28 subjects received one under postprandial conditions. Bioequivalence was established if the 90% confidence interval (CI) was 80.00–125.00%. The pharmacokinetic parameters were calculated via WinNonLin 8.1 software and the bioequivalence data were evaluated via Phoenix WinNonlin 8.1 statistics software. Results The geometric mean ratio (GMR) of the maximum observed concentration (Cmax), the area under the plasma concentration‒time curve (AUC) from time zero to the last sampling time (AUC0–t), and the AUC from time zero to infinity (AUC0–∞) from the test/reference formulation under fasting conditions were 90.50, 90.43, and 90.25, respectively. The 90% CIs were 83.75–97.79, 82.64–98.95, and 82.25–99.03, respectively. The GMRs of Cmax, AUC0–t, and AUC0–∞ after a high-fat meal were 96.85, 93.57, and 93.77, respectively; the 90% CIs were 88.43–106.07, 87.35–100.24, and 87.35–100.68, respectively. Conclusion The test and reference formulations of ondansetron HCl have bioequivalence for healthy adult subjects under fasting and postprandial conditions.
- 29 October 2024
- Published by Springer Nature in Drugs in R&D
- Vol. 24 (4) , 531-538
Open AccessBioequivalence Analysis of Ondansetron Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Two-Period Crossover Phase I Study
Background Ondansetron is a highly selective 5-HT3 receptor antagonist that alleviates nausea and vomiting. Bioequivalence evaluation ensures that the efficacy of generic drugs is consistent with that of the original drug. Objective The objective of this study was to evaluate the bioequivalence of ondansetron hydrochloride (HCl) tablets taken in single doses under fasting and postprandial conditions in healthy subjects. Methods In this randomized, open-label, two-cycle, crossover phase I study, liquid chromatography‒tandem mass spectrometry (LC‒MS/MS) was used to determine the ondansetron concentration in dipotassium-ethylenediaminetetraacetate (K2-EDTA) plasma after the subjects received a single 8 mg of ondansetron and reference formulation. Twenty-six healthy subjects received one tablet of ondansetron under fasting conditions and 28 subjects received one under postprandial conditions. Bioequivalence was established if the 90% confidence interval (CI) was 80.00–125.00%. The pharmacokinetic parameters were calculated via WinNonLin 8.1 software and the bioequivalence data were evaluated via Phoenix WinNonlin 8.1 statistics software. Results The geometric mean ratio (GMR) of the maximum observed concentration (Cmax), the area under the plasma concentration‒time curve (AUC) from time zero to the last sampling time (AUC0–t), and the AUC from time zero to infinity (AUC0–∞) from the test/reference formulation under fasting conditions were 90.50, 90.43, and 90.25, respectively. The 90% CIs were 83.75–97.79, 82.64–98.95, and 82.25–99.03, respectively. The GMRs of Cmax, AUC0–t, and AUC0–∞ after a high-fat meal were 96.85, 93.57, and 93.77, respectively; the 90% CIs were 88.43–106.07, 87.35–100.24, and 87.35–100.68, respectively. Conclusion The test and reference formulations of ondansetron HCl have bioequivalence for healthy adult subjects under fasting and postprandial conditions.
- Open Access
- 1 June 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 2273-2285
Pharmacokinetics and Bioequivalence of Apremilast Tablets in Chinese Healthy Subjects Under Fasting and Postprandial States
Objective: This study compared the pharmacokinetics, safety and bioequivalence (BE) of generic and original apremilast tablets in healthy Chinese subjects under fasting and postprandial conditions, providing sufficient evidence for abbreviated new drug application. Methods: A randomized, open-label, two-formulation, single-dose, two-period crossover pharmacokinetic study was performed. Thirty-two eligible healthy Chinese subjects were enrolled in fasting and postprandial studies, respectively. In each trial, subjects received a single 30-mg dose of the test or reference apremilast tablet, followed by a 7-day washout interval between periods. Serial blood samples were obtained for up to 48 h post-intake in each period, and the plasma concentrations of apremilast were determined by a validated method. The primary pharmacokinetic (PK) parameters, including the maximum plasma concentration (Cmax), the areas under the plasma concentration–time curve (AUC0-t, AUC0-∞), were calculated using the non-compartmental method. The geometric mean ratios of the two formulations and the corresponding 90% confidence intervals (CIs) were acquired for bioequivalence analysis. The safety of both formulations was also evaluated. Results: Under fasting and postprandial states, the PK parameters of the test drug were similar to those of the reference drug. The 90% CIs of the geometric mean ratios of the test to reference formulations were 94.09– 103.44% for Cmax, 94.05– 103.51% for AUC0-t, and 94.56– 103.86% for AUC0-∞ under fasting conditions, and 99.18– 112.48% for Cmax, 98.79– 106.02% for AUC0-t, and 98.95– 105.89% for AUC0-∞ under postprandial conditions, all of which were within the bioequivalence range of 80.00– 125.00%. Both formulations were well tolerated, and no serious adverse events occurred during the study. Conclusion: The trial confirmed that the PK parameters of the generic and original apremilast tablets were bioequivalent in healthy Chinese subjects under fasting and postprandial states, which met the predetermined regulatory standards. Both formulations were safe and well tolerated. Clinical Trial Registration: chinaDrugtrials.org.cn, identifier CTR20191056 (July 30, 2019); chictr.org.cn, identifier ChiCTR2300076806 (October 19, 2023).
- 1 June 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 2273-2285
Open AccessPharmacokinetics and Bioequivalence of Apremilast Tablets in Chinese Healthy Subjects Under Fasting and Postprandial States
Objective: This study compared the pharmacokinetics, safety and bioequivalence (BE) of generic and original apremilast tablets in healthy Chinese subjects under fasting and postprandial conditions, providing sufficient evidence for abbreviated new drug application. Methods: A randomized, open-label, two-formulation, single-dose, two-period crossover pharmacokinetic study was performed. Thirty-two eligible healthy Chinese subjects were enrolled in fasting and postprandial studies, respectively. In each trial, subjects received a single 30-mg dose of the test or reference apremilast tablet, followed by a 7-day washout interval between periods. Serial blood samples were obtained for up to 48 h post-intake in each period, and the plasma concentrations of apremilast were determined by a validated method. The primary pharmacokinetic (PK) parameters, including the maximum plasma concentration (Cmax), the areas under the plasma concentration–time curve (AUC0-t, AUC0-∞), were calculated using the non-compartmental method. The geometric mean ratios of the two formulations and the corresponding 90% confidence intervals (CIs) were acquired for bioequivalence analysis. The safety of both formulations was also evaluated. Results: Under fasting and postprandial states, the PK parameters of the test drug were similar to those of the reference drug. The 90% CIs of the geometric mean ratios of the test to reference formulations were 94.09– 103.44% for Cmax, 94.05– 103.51% for AUC0-t, and 94.56– 103.86% for AUC0-∞ under fasting conditions, and 99.18– 112.48% for Cmax, 98.79– 106.02% for AUC0-t, and 98.95– 105.89% for AUC0-∞ under postprandial conditions, all of which were within the bioequivalence range of 80.00– 125.00%. Both formulations were well tolerated, and no serious adverse events occurred during the study. Conclusion: The trial confirmed that the PK parameters of the generic and original apremilast tablets were bioequivalent in healthy Chinese subjects under fasting and postprandial states, which met the predetermined regulatory standards. Both formulations were safe and well tolerated. Clinical Trial Registration: chinaDrugtrials.org.cn, identifier CTR20191056 (July 30, 2019); chictr.org.cn, identifier ChiCTR2300076806 (October 19, 2023).
- 28 February 2024
- Published by Elsevier in Neuropharmacology
- Vol. 249, 109893
Exploring the therapeutic potential of cannabidiol for sleep deprivation-induced hyperalgesia
- 28 February 2024
- Published by Elsevier in Neuropharmacology
- Vol. 249, 109893
Exploring the therapeutic potential of cannabidiol for sleep deprivation-induced hyperalgesia